Sahakyan, Y. et al. 2022. Cost-utility of minimally invasive therapies vs. pharmacotherapy as initial therapy for benign prostatic hyperplasia: A Canadian healthcare payer perspective. Canadian Urological Association Journal. 17, 4 (Dec. 2022), 103–10. DOI:https://doi.org/10.5489/cuaj.8045.